Takeda Pharmaceutical (TAK) Interest & Investment Income (2017 - 2026)

Takeda Pharmaceutical's Interest & Investment Income history runs 10 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Interest & Investment Income changed N/A year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (changed N/A YoY), while the FY2026 annual figure was $1.4 billion, up 359.08% from the prior year.
• Interest & Investment Income was $1.3 billion for Q1 2026 at Takeda Pharmaceutical, up from $102.7 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $1.4 billion in Q3 2025 to a low of $102.7 million in Q4 2025.
• Historically, Interest & Investment Income has averaged $450.1 million across 5 years, with a median of $308.9 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Interest & Investment Income slumped 69.29% in 2023, then jumped 499.08% in 2025.
• A 5-year view of Interest & Investment Income shows it stood at $390.2 million in 2022, then declined by 20.08% to $311.9 million in 2023, then sank by 41.36% to $182.9 million in 2024, then sank by 43.87% to $102.7 million in 2025, then surged by 1211.6% to $1.3 billion in 2026.
• The last three Interest & Investment Income figures came in at $1.3 billion (Q1 2026), $102.7 million (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.